Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib Extension Study
NCT01178411Phase 2Completed
- Start
- Aug 2010
- Primary completion
- Jan 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tivantinib in solid tumor. Primary endpoint: Extent of Exposure to ARQ 197 in Participants Benefiting From Prior ARQ 197 Therapy up to 3021 days. Started Aug 2010; status: completed.
02
Drugs
tivantinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01178411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01178411.